Subsequently, given the strong correlation observed between the mRNA expression level of CD83 and tumor-infiltrating immune cells (TIICs), pathways involved in immunotherapeutic function, expression of immune checkpoints, and predictors of immunotherapy response, cohorts undergoing immunotherapy were included in the study to confirm the predictive significance of CD83 for the response to immunotherapy. The gene discussed is CD83; the disease is neoplasm.